Trial Profile
A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Aggressive B-cell lymphoma: NHL-13
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Jan 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Therapeutic Use
- 10 Dec 2013 Analysis comparing outcomes between male and female patents presented at the 56th Annual Meeting and Exposition of the American Society of Hematology.
- 14 Jun 2013 Final results presented at the 18th Congress of the European Haematology Association.
- 14 Jun 2013 The last patient received rituximab in September 2010. The study was closed after 148 events had been reached in March 2012. Final analysis was performed in March 2013.